New questionnaire aims to simplify allergy tracking in doctor visits
NCT ID NCT07315945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a simple symptom score questionnaire (SCST) is acceptable and useful for patients with allergic rhinitis during ENT check-ups. The goal is to see if this tool helps doctors monitor severity and response to treatment consistently. Thirty adults will participate, and the results could improve how allergies are tracked in routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a reliable, patient-friendly way to track allergic rhinitis severity in routine care, helping doctors tailor treatments.
- What could go wrong
- This is a small, early-stage study (30 participants) focused on tool validation, not treatment. The tool may not work for all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service d'ORL et de Chirurgie Cervico-faciale - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient herbal blend put to the test against hay fever
- Can a pinpoint pollen dose unmask allergy triggers?
- Can an antihistamine–steroid combo pill beat standard allergy meds?
- Allergy tablets under the tongue may cut hay fever drug use for years, massive real-world study suggests
- Allergy study seeks to pinpoint those most bothered by cats and birch pollen
- Dog allergy vaccine shows promise in small swedish trial